Gynecological cancers in patients with inflammatory rheumatic diseases

被引：0

作者：

Schmalzing, M. ^{[1
]}

Krockenberger, M. ^{[2
]}

Honig, A. ^{[3
]}

Tony, H. -P. ^{[1
]}

机构：

[1] Univ Klinikum Wurzburg, Zentrum Innere Med, Med Klin & Poliklin 2, Rheumatol Klin Immunol, Oberdurrbacher Str 6, D-97080 Wurzburg, Germany

[2] Univ Klinikum Wurzburg, Frauenklin & Poliklin, Wurzburg, Germany

[3] Kathol Klinikum Mainz, Klin Frauenheilkunde & Geburtshilfe, Mainz, Germany

来源：

ZEITSCHRIFT FUR RHEUMATOLOGIE | 2016年 / 75卷 / 01期

关键词：

Immunosuppression; Breast cancer; Ovarian cancer; Cervical cancer; Systemic lupus erythematosus; BREAST-CANCER; FOLLOW-UP; INTRAEPITHELIAL NEOPLASIA; THERAPY; RISK; ARTHRITIS; WOMEN; METAANALYSIS; DIAGNOSIS; SURVIVAL;

D O I：

10.1007/s00393-016-0044-z

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

The risk of gynecological cancers in patients with inflammatory rheumatic diseases only seems to be elevated with respect to cervical cancer and mainly in patients with systemic lupus erythematosus. There is increasing evidence for an influence of the immune system on tumor control of gynecological malignancies; however, an adverse influence of immunosuppressive treatment in rheumatic patients was indicated only for the risk of cervical cancer. In contrast, biologics could not be shown to cause an increased risk of cervical cancer but data on this topic are limited. General screening recommendations exist for breast cancer and cervical cancer. Recommendations for follow-up after oncological treatment are presented. Because of limited evidence immunosuppressive and biological treatment should be applied with great restraint at least within the first 5 years after curative oncological treatment also for gynecological tumors. As far as breast cancer is concerned an even longer interval is under discussion.

引用

页码：63 / 67

页数：5

共 50 条

[1] Gynäkologische Malignome bei Patientinnen mit rheumatisch‑entzündlichen SystemerkrankungenGynecological cancers in patients with inflammatory rheumatic diseases
M. Schmalzing
M. Krockenberger
A. Honig
H.‑P. Tony
Zeitschrift für Rheumatologie, 2016, 75 (1) : 63 - 68
[2] Inflammatory rheumatic diseases and pregnancy
Klimaszyk, Katarzyna
Wender-Ozegowska, Ewa
Kedzia, Malgorzata
GINEKOLOGIA POLSKA, 2021, 92 (09) : 663 - 667
[3] Pregnancy and inflammatory rheumatic diseases
Fischer-Betz, R.
Spaethling-Mestekemper, S.
ZEITSCHRIFT FUR RHEUMATOLOGIE, 2013, 72 (07): : 669 - 680
[4] Rationale for bone marrow examination in patients with inflammatory rheumatic diseases
Richter, Jutta G.
Gossen, Pascal
Germing, Ulrich
Blum, Sabine
Hildebrandt, Barbara
Braunstein, Stefan
Huscher, Doerte
Schneider, Matthias
WIENER KLINISCHE WOCHENSCHRIFT, 2009, 121 (21-22) : 690 - 699
[5] Exercises in Inflammatory Rheumatic Diseases
Soy Bugdayci, Derya
Paker, Nurdan
TURKIYE FIZIKSEL TIP VE REHABILITASYON DERGISI-TURKISH JOURNAL OF PHYSICAL MEDICINE AND REHABILITATION, 2014, 60 : S50 - S57
[6] Pregnancy and inflammatory rheumatic diseases
Fischer-Betz, R.
Gromnica-Ihle, E.
ZEITSCHRIFT FUR RHEUMATOLOGIE, 2010, 69 (07): : 633 - 641
[7] Inflammatory rheumatic diseases in the elderly
Schuetz, N.
Sixdorf, U.
Maerker-Hermann, E.
DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, 2012, 137 (15) : 793 - 798
[8] Association between endometriosis and gynecological cancers: a critical review of the literature
Kalaitzopoulos, Dimitrios Rafail
Mitsopoulou, Angeliki
Iliopoulou, Sotiria Maria
Daniilidis, Angelos
Samartzis, Eleftherios P.
Economopoulos, Konstantinos P.
ARCHIVES OF GYNECOLOGY AND OBSTETRICS, 2020, 301 (02) : 355 - 367
[9] Management of inflammatory rheumatic diseases during and after malignancies
Schmalzing, Marc
ZEITSCHRIFT FUR RHEUMATOLOGIE, 2022, 81 (09): : 766 - 777
[10] Managing comorbidities of inflammatory rheumatic diseases
de Groot, K.
Maerker-Hermann, E.
INTERNIST, 2011, 52 (06): : 688 - +

← 1 2 3 4 5 →